Calendar of events

October 2 – 4 2023 | Boston, MA

Unlocking the Full Potential of Bi, Tri- & Multispecfic Antibody Target Discovery, Mechanistic Diversity & Clinical Translation to Maximize Therapeutic Windows

Be at the forefront of the Bispecific space as it goes head-to-head with cell therapy to transform oncology. Among numerous innovations in cancer immunotherapy, Bispecific antibody treatments have never been more promising with continuous clinical updates and approvals over the last year, including the huge waves seen in multiple myeloma and lymphoma treatment.

The World Bispecific Summit returns for its 14th year with an enriched program boasting comprehensive coverage of all the key discovery, pre-clinical, and clinical challenges including design, clinical, regulatory, and combination strategies. Led by the industry’s brightest minds from the likes of Sanofi, Regeneron, the FDA, Alligator Biosciences, and Amgen, it’s the perfect platform to celebrate wins, work through challenges, and establish connections with the leading pharma, biotech, and academic KOLs.

Access your copy of the full event guide with 35+ world-class speakers. Beacon’s Bispecific expert, Flavio Lima Bianchi, will be joining this leading speaker faculty and opening the conference with a review of the landscape, covering the past, present, and future of biologics.

Deep dive into novel target selection, immune cell modulators, target selection and pre-clinical/clinical readouts and gain holistic insight on the current state-of-play in the bispecific landscape to supercharge your own pipeline from discovery through to IND approval.

To join our longstanding Bispecific community in Boston, register your place here.

October 10 – 12 2023 | Boston, MA

The mRNA Cancer Vaccine Summit 2023 comes to Boston as the cancer vaccine community is on the cusp of something truly exciting.

This is the first and only forum dedicated to showcasing mRNA cancer vaccine technology advances, translational insights, and critical clinical updates from the global leaders working towards effective harnessing of neoantigens and developing successful tailor-made mRNA cancer vaccines.

Unite with mRNA cancer vaccine, oncology, and immuno-oncology leaders and stay up to date with the most innovative cancer therapies, as our world-class speakers navigate through:

• Next-generation techniques in personalized mRNA cancer vaccines to develop a more effective vaccine
• Optimizing the antigen selection process to ensure high clinical activity & high-quality immune responses
• Understanding the standards & regulatory requirements for mRNA cancer vaccines for rapid approvals & commercial readiness

With 60+ attendees, 24 world-class speakers including Beacon’s Cancer Vaccine Research Lead, Megan Taylor, 3 roundtable discussions, 1 focus day, and over 6 hours of dedicated networking, ensure you join us to truly remain ahead of the curve as we revolutionize the next era of cancer immunotherapy.

October 16 – 19, 2023 | San Diego, CA

The ADC renaissance shows no sign of slowing down with the ground-breaking approval of ELAHERE for platinum-resistant ovarian cancer, Pfizer’s jaw-dropping acquisition of Seagen for $43 billion, and BMS’ $1 billion+ pact with Tubulis. There has been no better time to reunite the World ADC community and invest in progressing ADCs to front-line treatments for patients.

The highly anticipated 14^th World ADC San Diego returns as the world’s largest industry-dedicated discussion and networking forum addressing and overcoming the challenges in end-to-end ADC development.

Joining 120+ industry-leading speakers and reviewing the current state of the ADC landscape, is Beacon’s expert Account Manager, Jake Morris. This is one not to be missed.

Don’t miss out on the chance to reunite with the antibody-drug conjugate community while reflecting on the exciting year that ADCs have had, and building momentum for the future of this innovative field.

October 30 – November 2 2023 | Boston, MA

This Fall, the world’s longest-standing and most comprehensive TPD meeting, the 6th Targeted Protein Degradation Summit, returns to Boston in 2023 as the trusted, definitive, end-to-end forum for the global network of protein degradation drug developers.

Join over 100 world-class TPD experts alongside a further 600 of your peers as the community assembles to hear breaking clinical updates and outstanding new innovations, and problem-solve unifying challenges.

Beacon’s Lead TPD Research Analyst, Katie Spooner, will be exploring the Clinical & Preclinical Activity of Novel Bifunctional Degraders Across the TPD Field, on Conference Day 1, as part of the Clinical Development track, at 5:10 pm; this is not one to be missed with some exclusive insights from the Beacon database!

Across 4 days, 4 tracks of content are split based on the stage of drug development: target ID, lead optimization, preclinical, and clinical. Choose the track that your expertise is best suited to. With a brand-new pre-conference day dedicated to TPD in CNS, revamped workshops, and the KOL Future Advisory Panel, this is the most all-encompassing TPD event yet.

November 6 – 9, 2023 | Boston, MA

Recent approvals from Sarepta, Bluebird Bio, and PTC Therapeutics, and news of expanding CNS pipelines have highlighted that we are currently on the cusp of a next-generation of neurological gene therapies, and the 5th Gene Therapy for Neurological Disorders Summit is here to help you propel the next wave of innovation.

This meeting will enable you to overcome your Discovery, Preclinical and Clinical development challenges, from capsid engineering to preclinical model selection, immunogenicity, drug delivery, and regulation; this is the only cover-to-cover, comprehensive 4-day discussion full of need-to-know and practical insights.

Now that the neurological gene therapy field has been given a renewed sense of direction, this is the opportunity for the community to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders.

Join your peers this November from all phases of neurological gene therapy development, including Discovery, Preclinical Development, Translation, and Clinical Development.

November 28-30, 2023 | Boston, MA

Accelerate the Clinical Translation of CAR-T, Treg & MSC-Based Therapies with Improved Efficacy, Durability & Safety to Revolutionize Curative Care for Chronic Autoimmune Disease

The Cell Therapy for Autoimmune Disease Summit is an unparalleled, pioneering event that unites leading experts and stakeholders in this exciting emerging field. This groundbreaking summit is a platform for sharing and discussing the latest advances in pre-clinical, translational, and clinical development across various cell types including CAR-T, Tregs, and MSCs.

With 75+ attendees, 30+ world-class speakers including the likes of Cabaletta, Artiva, Abata, and Novartis delving into everything from new pre-clinical and clinical data, developing therapies with a high safety profile, innovative trial design, endpoints, and over 6 hours of dedicated networking, ensure you join us to revolutionize the treatment landscape for chronic autoimmune diseases.

Our Cell Therapy Research Lead, Rachel East, joins the line-up, setting the scene, with a comprehensive review of the past, present & future of the Cell Therapy landscape, at 9:00 a.m. Find out more of her session details here; this is one not to be missed!

December 12 – 14 2023 | Boston, MA

Recent years have seen highly promising and rapid advances in the pre-clinical development and clinical evolution of oncolytic virotherapies. They are increasingly being recognized as a therapy with huge potential to change the landscape for cancer immunotherapy.

The global, leading, and hotly anticipated annual 8^th Oncolytic Virotherapy Summit returns to Boston this December, as the industry’s definitive, and most comprehensive forum. Bringing you 29+ world-class speakers from key stakeholders from leading biopharma, this event will be showcasing brand new pivotal data to ensure a pathway of success for regulatory approval of OV drugs.

This forum will unite 80+ OV trailblazers across sessions spanning Early Discovery, Translation, Clinical Development, Chemistry, Manufacturing & Controls (CMC), and Regulations to overcome the industry’s largest and most critical bottlenecks.

Beacon’s Oncolytic Viruses Research Lead, Megan Taylor, will be providing a drug and trial landscape analysis as well as an examination of the preclinical landscape, and what it can tell us about the potential future of OVs. This is one not to be missed.

Join the only end-to-end forum dedicated to emerging and advancing OV immunotherapies and contribute to driving the next wave of clinical approvals, towards a landscape of more effective anti-cancer drugs generating anti-tumour immune response within patients in need.